Supplementary MaterialsCEOR-11-159-192235. of cost per QALY gained. Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses. Results Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost (279,872) vs other comparators in biologic-na?ve AS patients in the base case analysis, it dominated other biologics as a result. Golimumab had another highest QALYs… Continue reading Supplementary MaterialsCEOR-11-159-192235. of cost per QALY gained. Robustness of results was